Currently, Wegovy is FDA approved for the following: Children ages 12 years or older with a body mass index (BMI) at or above the 95th percentile for their sex and age Adults with a BMI at or above 30 Adults with a BMI at or above 27 and at least one weight-related health condition, such as heart disease, diabetes, high blood pressure, or sleep apnea Adults with a BMI at or above 27 with established cardiovascular disease and a risk of major adverse cardiovascular events (like heart attack or stroke) Adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis Note that there are slightly different prescribing rules for Wegovy pills versus Wegovy injections
This intelligent modulation suits chronic conditions where the goal is restoration of normal function rather than complete suppression
Additionally, sequential use of the medications, starting with GLP-1 receptor agonists, appears to lead to more significant weight loss
Advocates got into the fight in the 1980s, as families, peers, clinicians, and researchers demanded clozapine's return